TY - JOUR
T1 - Localization of Microfibrillar-Associated Protein 4 (MFAP4) in Human Tissues
T2 - Clinical Evaluation of Serum MFAP4 and Its Association with Various Cardiovascular Conditions
AU - Wulf-Johansson, Helle
AU - Lock Johansson, Sofie
AU - Schlosser, Anders
AU - Trommelholt Holm, Anne
AU - Melholt Rasmussen, Lars
AU - Mickley, Hans
AU - Diederichsen, Axel Cosmus Pyndt
AU - Munkholm, Henrik
AU - Poulsen, Tina Svenstrup
AU - Tornøe, Ida
AU - Nielsen, Vicki
AU - Marcussen, Niels
AU - Vestbo, Jørgen
AU - Sækmose, Susanne Gjørup
AU - Holmskov, Uffe
AU - Sorensen, Grith Lykke
PY - 2013
Y1 - 2013
N2 - Microfibrillar-associated protein 4 (MFAP4) is located in the extracellular matrix (ECM). We sought to identify tissues with high levels of MFAP4 mRNA and MFAP4 protein expression. Moreover, we aimed to evaluate the significance of MFAP4 as a marker of cardiovascular disease (CVD) and to correlate MFAP4 with other known ECM markers, such as fibulin-1, osteoprotegerin (OPG), and osteopontin (OPN). Quantitative real-time PCR demonstrated that MFAP4 mRNA was more highly expressed in the heart, lung, and intestine than in other elastic tissues. Immunohistochemical studies demonstrated high levels of MFAP4 protein mainly at sites rich in elastic fibers and within blood vessels in all tissues investigated. The AlphaLISA technique was used to determine serum MFAP4 levels in a clinical cohort of 172 patients consisting of 5 matched groups with varying degrees of CVD: 1: patients with ST elevation myocardial infarction (STEMI), 2: patients with non-STEMI, 3: patients destined for vascular surgery because of various atherosclerotic diseases (stable atherosclerotic disease), 4: apparently healthy individuals with documented coronary artery calcification (CAC-positive), and 5: apparently healthy individuals without signs of coronary artery calcification (CAC-negative). Serum MFAP4 levels were significantly lower in patients with stable atherosclerotic disease than CAC-negative individuals (p
AB - Microfibrillar-associated protein 4 (MFAP4) is located in the extracellular matrix (ECM). We sought to identify tissues with high levels of MFAP4 mRNA and MFAP4 protein expression. Moreover, we aimed to evaluate the significance of MFAP4 as a marker of cardiovascular disease (CVD) and to correlate MFAP4 with other known ECM markers, such as fibulin-1, osteoprotegerin (OPG), and osteopontin (OPN). Quantitative real-time PCR demonstrated that MFAP4 mRNA was more highly expressed in the heart, lung, and intestine than in other elastic tissues. Immunohistochemical studies demonstrated high levels of MFAP4 protein mainly at sites rich in elastic fibers and within blood vessels in all tissues investigated. The AlphaLISA technique was used to determine serum MFAP4 levels in a clinical cohort of 172 patients consisting of 5 matched groups with varying degrees of CVD: 1: patients with ST elevation myocardial infarction (STEMI), 2: patients with non-STEMI, 3: patients destined for vascular surgery because of various atherosclerotic diseases (stable atherosclerotic disease), 4: apparently healthy individuals with documented coronary artery calcification (CAC-positive), and 5: apparently healthy individuals without signs of coronary artery calcification (CAC-negative). Serum MFAP4 levels were significantly lower in patients with stable atherosclerotic disease than CAC-negative individuals (p
U2 - 10.1371/journal.pone.0082243
DO - 10.1371/journal.pone.0082243
M3 - Journal article
C2 - 24349233
VL - 8
JO - P L o S One
JF - P L o S One
SN - 1932-6203
IS - 12
M1 - e82243
ER -